Trailing-twelve-month (TTM) revenue is $16.57 Billion with a year-over-year growth of (8.35%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $4,133,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q4 FY2025Period ended 2025-12-31 | $4,080,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-12 |
| Q1 FY2026Period ended 2026-03-31 | $4,163,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-28 |
| Q2 FY2026Period ended 2026-06-30 | $4,189,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $16,565,000,000 |
Current P/S: $32,689,451,200 market capitalization ÷ $16,565,000,000 TTM revenue = 1.97x.
Market capitalization source: FMP quote. Quote observed 2026-09-10T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $4.19B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-10T20:00:01.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Adult care products | N/A | N/A | N/A | N/A | N/A | $1.9B |
| Away from Home Professional Products | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20102010-12-31 · USD | FY20112011-12-31 · USD | FY20122012-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|
| Asia, Latin America and Other | $6.6B | $7.5B | $7.9B | N/A |
| Canada | $684M | $726M | $718M | N/A |
| Europe | $3.2B | $3.4B | $3.2B |
$16.57B
$16.57 Billion
(8.35%)
vs. $18.07B a year ago (TTM)
(2.69%)
5 Year compound annual growth rate
1 Year
(8.35%)
3 Year
(6.62%)
5 Year
(2.69%)
10 Year
(1.00%)
15 Year
(1.36%)
20 Year
+0.10%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $17.22B | ($2.84B) | (14.17%) |
| 2024 | $20.06B | ($373.00M) | (1.83%) |
| 2023 | $20.43B | +$256.00M | +1.27% |
| 2022 | $20.18B | +$735.00M | +3.78% |
| 2021 | $19.44B | +$300.00M | +1.57% |
| 2020 |
TTM Growth
(8.35%)
3-Year CAGR
(6.62%)
5-Year CAGR
(2.69%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-10T20:00:01.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| $1.8B |
| Consumer Tissue | $6.7B | $6.0B | $6.2B | $6.3B | $6.2B | N/A |
|---|
| Consumer tissue products | N/A | N/A | N/A | N/A | N/A | $4.1B |
|---|
| Diapers | N/A | N/A | N/A | N/A | N/A | $6.8B |
|---|
| Feminine care products | N/A | N/A | N/A | N/A | N/A | $1.7B |
|---|
| K-C Professional | $3.0B | $3.1B | $3.3B | $3.4B | N/A | N/A |
|---|
| Personal Care | $9.3B | $10.3B | $10.6B | $10.7B | N/A | N/A |
|---|
| UNITED STATES | $10.5B | $10.5B | $10.5B | $10.1B |
|---|
| $19.14B |
| +$690.00M |
| +3.74% |
| 2019 | $18.45B | ($36.00M) | (0.19%) |
| 2018 | $18.49B | +$227.00M | +1.24% |
| 2017 | $18.26B | +$57.00M | +0.31% |
| 2016 | $18.20B | ($389.00M) | (2.09%) |
